- Published on
Clinical Toxicology — Sedative-Hypnotic Agents
1. Overview
Sedative-hypnotic agents are medications that reduce central nervous system (CNS) activity, producing effects ranging from mild drowsiness to sleep, anesthesia, coma, and respiratory depression.
The original chapter groups together several pharmacologically different substances. For modern toxicology, it is important to distinguish nonbenzodiazepine hypnotics, older sedative drugs, anxiolytics, and opioids rather than treating them as one toxicologic class.
The principal danger in severe sedative-hypnotic poisoning is loss of airway protection and inadequate ventilation.
Other important complications include hypotension, aspiration, hypothermia, cardiac dysrhythmias, and prolonged coma.
Although many isolated overdoses resolve with supportive care, certain older agents—particularly chloral hydrate, meprobamate, and glutethimide—can cause severe or prolonged toxicity.
There is no universal antidote. Treatment depends on the specific drug, its formulation, and any coingested substances.
2. Classification and important agents
Nonbenzodiazepine hypnotics: Z-drugs
The principal modern Z-drugs are:
Zolpidem: Marketed as Ambien and in several immediate-release, extended-release, sublingual, and oral-spray formulations.
Zaleplon: Marketed as Sonata.
Eszopiclone: Marketed as Lunesta.
Zopiclone is also widely used in many countries outside the United States.
These drugs are prescribed for insomnia. They act at the benzodiazepine binding site of the GABA-A receptor complex despite being chemically distinct from benzodiazepines.
Older sedative-hypnotics
Chloral hydrate: Historically used for insomnia and procedural sedation. It can cause serious ventricular dysrhythmias in overdose.
Clomethiazole: Also spelled chlormethiazole; used in certain countries for supervised alcohol withdrawal and other selected indications.
Meprobamate: An older anxiolytic and sedative associated with profound coma and cardiovascular collapse after overdose.
Glutethimide: A withdrawn hypnotic that can cause anticholinergic manifestations, prolonged or recurrent coma, and respiratory failure.
Methaqualone: Formerly marketed as Quaalude; associated with sedation, coma, and misuse.
Ethchlorvynol and methyprylon: Older sedative-hypnotics that are no longer routinely marketed in the United States.
Availability varies internationally.
Drugs requiring separate classification
Buspirone is not a conventional sedative-hypnotic. It is a nonbenzodiazepine anxiolytic acting mainly through serotonin 5-HT1A receptors. It lacks the prominent GABA-mediated sedation, anticonvulsant activity, and muscle relaxation associated with traditional sedatives.
Tramadol is an opioid analgesic, not a sedative-hypnotic. It also inhibits serotonin and norepinephrine reuptake and can produce respiratory depression, seizures, and serotonin syndrome.
These two medications should have separate drug-specific toxicology considerations.
3. Mechanisms of toxicity
GABA-A receptor modulation
Zolpidem, zaleplon, and eszopiclone enhance inhibitory neurotransmission through GABA-A receptor complexes.
Z-drugs differ in their receptor-subunit selectivity, duration of action, and pharmacokinetics.
Excessive GABA-mediated inhibition causes impaired consciousness, ataxia, and potentially respiratory depression.
Chloral hydrate
Chloral hydrate is rapidly converted to trichloroethanol, its principal active sedative metabolite.
It also has important cardiotoxic properties that may sensitize the myocardium to catecholamines.
Consequently, chloral hydrate overdose can produce serious ventricular dysrhythmias in addition to CNS depression.
Meprobamate
Meprobamate produces barbiturate-like CNS depression through actions involving GABA-A receptors.
Severe overdose can cause profound coma, hypotension, and respiratory failure.
Glutethimide
Glutethimide has sedative effects and may produce antimuscarinic manifestations.
Delayed absorption and altered gastrointestinal motility can contribute to prolonged toxicity.
Clomethiazole
Clomethiazole enhances GABA-A receptor-mediated inhibitory activity.
It can produce significant respiratory depression, particularly when combined with alcohol or other sedatives.
4. Toxic dose and important risk factors
There is no single toxic-dose threshold applicable to all these medications.
The toxicity of a given ingestion depends on the substance, formulation, amount, age, underlying illness, and concurrent medications.
Z-drugs
Isolated Z-drug overdoses often cause drowsiness, confusion, ataxia, or transient coma.
Life-threatening respiratory depression is less common after isolated exposure but becomes substantially more concerning with alcohol, opioids, benzodiazepines, or other CNS depressants.
Chloral hydrate
Chloral hydrate has a relatively narrow safety margin.
The Royal Children’s Hospital Melbourne guideline identifies severe toxicity after doses exceeding approximately 100 mg/kg.
However, smaller exposures may still require evaluation depending on age and clinical findings.
Meprobamate
Large ingestions can produce profound hypotension, coma, and prolonged respiratory failure.
Children
Accidental ingestion of even a relatively small number of tablets may cause clinically important sedation in young children.
No universal pediatric safe-dose threshold should be inferred from adult experience.
Risk factors for severe poisoning
Important factors include concurrent alcohol or opioid use, sleep apnea, chronic lung disease, advanced age, impaired liver metabolism, large or modified-release ingestions, and intentional multidrug overdose.
5. Clinical manifestations
Neurologic effects
Typical findings include:
- Drowsiness.
- Dysarthria.
- Ataxia.
- Impaired judgment.
- Confusion.
- Nystagmus.
- Reduced responsiveness.
- Stupor or coma.
Paradoxical agitation, hallucinations, disinhibition, or abnormal behavior may occasionally occur.
Respiratory depression
Hypoventilation is the principal immediately life-threatening complication.
Severe intoxication can cause airway obstruction, hypoxemia, hypercapnia, and respiratory arrest.
Aspiration may occur following vomiting or loss of airway reflexes.
Cardiovascular effects
Hypotension and bradycardia are possible.
Most isolated Z-drug overdoses do not produce severe primary cardiotoxicity.
Chloral hydrate is an important exception, as it may cause ventricular ectopy, ventricular tachycardia, and ventricular fibrillation.
Temperature abnormalities
Hypothermia may develop during prolonged unconsciousness.
Gastrointestinal effects
Nausea and vomiting may occur.
Large chloral hydrate ingestions can also cause severe gastrointestinal irritation, bleeding, and corrosive injury.
Complications of prolonged coma
These include aspiration-related lung injury, pressure injuries, rhabdomyolysis, acute kidney injury, and hypoxic brain injury.
6. Agent-specific clinical syndromes
Zolpidem, zaleplon, and eszopiclone
These medications typically produce sedation and impaired coordination.
Severe cases can involve coma, especially after coingestion with other depressants.
A distinct concern during therapeutic use is complex sleep behavior, such as sleepwalking, sleep-driving, preparing food, or engaging in other activities while not fully awake.
Such behaviors may cause serious injuries or death.
The FDA requires boxed warnings for zolpidem, zaleplon, and eszopiclone.
Patients who experience a complex sleep behavior should discontinue the responsible medication and obtain medical assessment.
Chloral hydrate
Chloral hydrate toxicity may develop rapidly, often within the first hour.
Severe poisoning can cause profound CNS depression, hypotension, ventricular dysrhythmias, and gastrointestinal mucosal injury.
Cardiac monitoring is essential after significant chloral hydrate ingestion.
Meprobamate
Severe overdose may cause deep coma, respiratory failure, and circulatory shock.
Gastrointestinal concretions and delayed absorption have been described.
The duration of toxicity may be prolonged.
Glutethimide
Glutethimide may cause anticholinergic findings, thick bronchial secretions, hyperthermia, seizures, and prolonged or recurrent coma.
Clomethiazole
Toxicity is dominated by sedation and respiratory depression.
The interaction with alcohol is particularly dangerous.
Clomethiazole should be used for alcohol withdrawal only in appropriate supervised settings, not routinely for community-based withdrawal management.
Buspirone
Isolated overdose generally causes less profound CNS depression than traditional hypnotics.
Dizziness, nausea, vomiting, and drowsiness may occur.
A major concern is serotonin syndrome, particularly when buspirone is combined with monoamine oxidase inhibitors or other serotonergic medications.
Tramadol
Tramadol overdose requires a separate opioid-focused assessment.
Important complications include respiratory depression, recurrent seizures, serotonin syndrome, and coma.
Naloxone is appropriate for clinically important opioid-mediated respiratory depression, but it does not reverse all aspects of tramadol toxicity.
7. Diagnosis and investigations
Diagnosis is primarily clinical.
Exposure history
Identify the exact drug, dose, formulation, time of ingestion, chronic medication use, and coingestants.
Determine whether alcohol, opioids, antidepressants, or additional sedatives were involved.
Initial assessment
Evaluate airway protection, respiratory rate, breathing depth, oxygenation, circulation, temperature, and consciousness.
Pulse oximetry alone may fail to recognize hypoventilation, especially when supplemental oxygen is administered.
Capnography can help identify inadequate ventilation.
Laboratory testing
Investigations may include:
- Bedside blood glucose.
- Electrolytes.
- Creatinine and kidney function.
- Blood gas when hypoventilation or major metabolic disturbance is suspected.
- ECG.
- Acetaminophen and salicylate concentrations after deliberate or uncertain overdose.
- Creatine kinase in patients with prolonged coma or substantial muscle injury.
Drug testing
Routine urine drug screens may not detect Z-drugs or several older sedative agents.
A negative benzodiazepine or general toxicology immunoassay does not exclude sedative-hypnotic poisoning.
Specialized serum drug concentrations are occasionally available but rarely guide immediate treatment.
8. Differential diagnosis
Other causes of impaired consciousness include benzodiazepines, barbiturates, opioids, ethanol, antipsychotics, antidepressants, and antiseizure medications.
Non-toxicologic causes include hypoglycemia, intracranial hemorrhage, stroke, infection, hypoxia, electrolyte disturbances, and metabolic encephalopathy.
Important clinical principle
Do not assume an unconscious patient has isolated sedative poisoning solely because a sedative medication was found nearby.
Persistent coma, seizures, significant ECG abnormalities, or other atypical findings require assessment for additional diagnoses and coingestants.
9. Initial treatment
Airway and ventilation
Supportive care is the cornerstone of treatment.
Position and monitor the patient appropriately, assess airway reflexes, and provide oxygen when indicated.
Assisted ventilation is required for clinically important hypoventilation.
Endotracheal intubation may be necessary when the patient cannot protect the airway or maintain adequate ventilation.
Circulation
Establish intravenous access and monitor blood pressure.
Treat clinically important volume depletion with appropriately titrated crystalloid.
Persistent shock may require a vasopressor, commonly norepinephrine, while addressing the specific cause.
Neurologic complications
Treat hypoglycemia immediately.
Use benzodiazepines for toxin-associated seizures when indicated.
Persistent seizures require escalation according to contemporary status epilepticus protocols.
Opioid coingestion
If opioid toxicity is suspected and the patient has clinically important respiratory depression, administer naloxone while supporting ventilation.
Naloxone is not an antidote for isolated zolpidem, chloral hydrate, or meprobamate toxicity.
10. Flumazenil
Flumazenil is a competitive antagonist at the benzodiazepine binding site of the GABA-A receptor complex.
It can reverse sedation caused by benzodiazepines and may also reverse the effects of some Z-drugs.
However, routine flumazenil is not recommended for undifferentiated sedative-hypnotic overdose.
Potential role
It may be considered in carefully selected patients with a strongly suspected isolated benzodiazepine or Z-drug exposure who are not at increased seizure risk.
Important risks
Flumazenil may precipitate seizures in patients with:
- Chronic benzodiazepine exposure or dependence.
- Coingestion of proconvulsant substances.
- Certain mixed antidepressant overdoses.
- Underlying seizure disorders in which benzodiazepines provide seizure control.
Flumazenil can also cause abrupt agitation or withdrawal.
Chloral hydrate
An isolated historical report of response to flumazenil does not establish effectiveness.
Flumazenil is not a proven antidote for chloral hydrate poisoning.
The decision to use flumazenil should involve experienced clinicians and poison-center advice.
11. Chloral hydrate cardiotoxicity
Recognition
Severe chloral hydrate poisoning can cause ventricular ectopy, wide-complex tachycardia, ventricular fibrillation, and circulatory collapse.
Obtain a 12-lead ECG and maintain continuous monitoring.
Immediate management
Correct hypoxemia, important electrolyte abnormalities, and other contributing factors.
Unstable ventricular dysrhythmias require appropriate resuscitation and electrical treatment.
Beta blockers
Historical case reports describe successful treatment of chloral hydrate-associated ventricular dysrhythmias with propranolol.
The Royal Children’s Hospital Melbourne guideline also identifies propranolol or esmolol as treatment options.
However, the evidence comes mainly from case reports and specialist experience.
Beta blockers can aggravate hypotension or myocardial dysfunction and therefore should not be administered automatically to every poisoned patient.
Their use should be individualized with medical toxicology and critical-care consultation.
Catecholamine sensitivity
Chloral hydrate may increase susceptibility to catecholamine-triggered dysrhythmias.
Vasoactive therapy in these patients requires particularly careful assessment and titration.
12. Gastrointestinal decontamination
Induced vomiting
Do not induce vomiting.
Gastric lavage
Routine gastric lavage is not recommended.
The risk of aspiration is important because sedation can develop rapidly.
Activated charcoal
A single dose may be considered following a substantial recent ingestion when the airway is protected.
However, routine charcoal administration is not appropriate in patients who are already significantly sedated or vomiting.
For isolated Z-drug poisoning, supportive care is generally sufficient, and charcoal is usually unnecessary.
Whole-bowel irrigation
Whole-bowel irrigation is not recommended routinely for sedative-hypnotic overdose.
Historical reports of delayed absorption or concretions after meprobamate and glutethimide ingestion do not establish a general benefit from this intervention.
Its use should be considered only in unusual circumstances after specialist toxicology consultation.
13. Enhanced elimination
Most sedative-hypnotic poisonings do not require extracorporeal treatment.
Meprobamate
Meprobamate is a notable exception.
Published case reports demonstrate clinically meaningful removal by hemodialysis, hemoperfusion, and continuous hemodiafiltration.
For example, a 2013 report documented that continuous venovenous hemodiafiltration contributed substantially to total meprobamate clearance during severe poisoning.
Clinical interpretation
Extracorporeal treatment may be considered in exceptional cases involving profound coma, respiratory failure, persistent shock, or progressive toxicity.
However, the evidence is largely limited to case reports rather than controlled outcome studies.
Chloral hydrate
Hemodialysis has been considered in severe chloral hydrate poisoning with persistent cardiovascular instability or refractory dysrhythmias.
Its use remains an uncommon specialist decision.
Z-drugs
There is no established indication for routine hemodialysis to remove zolpidem, zaleplon, or eszopiclone.
General rule
A large ingestion alone does not establish a need for dialysis.
The decision must account for the specific drug, clinical severity, expected clearance, and available evidence.
14. Withdrawal and dependence
Repeated use of some sedative-hypnotic medications can cause tolerance and physical dependence.
Abrupt discontinuation after prolonged high-dose exposure may produce:
- Anxiety.
- Insomnia.
- Tremor.
- Agitation.
- Autonomic instability.
- Occasionally seizures.
Withdrawal risk varies markedly between agents and treatment patterns.
Z-drugs
Withdrawal symptoms and dependence have been documented, particularly after prolonged or high-dose use.
Older sedatives
Meprobamate, clomethiazole, and other older sedatives may produce clinically important dependence and withdrawal.
Management
Patients at risk of withdrawal require individualized assessment.
In selected dependent patients, gradual reduction under medical supervision is safer than abrupt discontinuation.
15. Pregnancy and lactation
The historical FDA pregnancy letter categories are obsolete.
Safety considerations vary by drug.
Z-drugs
Zolpidem and related medications may be used in selected circumstances after individualized assessment, but risks include maternal sedation, impaired functioning, and possible neonatal effects after late-pregnancy exposure.
Older sedatives
Chloral hydrate, meprobamate, and clomethiazole have limited contemporary pregnancy safety data.
They are generally not preferred when better-characterized treatments are available.
Buspirone
Available pregnancy information is limited but does not support automatically categorizing buspirone with the risks of older barbiturate-like hypnotics.
Tramadol
Tramadol presents opioid-specific risks, including neonatal respiratory depression and withdrawal after prolonged maternal use.
Breastfeeding
Lactation guidance should be agent-specific.
Some hypnotics enter breast milk in low quantities, whereas older sedatives may have less reassuring evidence.
Monitor infants for unusual sleepiness, poor feeding, or inadequate breathing when a potentially sedating medication is used during breastfeeding.
16. Monitoring and disposition
Minor isolated exposures
Selected patients with minor, isolated, immediate-release Z-drug ingestion who remain asymptomatic may require only limited observation and poison-center assessment.
Significant exposure
Patients with altered consciousness, respiratory depression, hypotension, significant coingestants, or uncertain formulations require emergency evaluation.
Prolonged toxicity
Extended-release hypnotics and older agents such as meprobamate or glutethimide may cause prolonged effects.
Observation must therefore be individualized.
Hospital admission
Admission is appropriate for persistent sedation, respiratory compromise, hemodynamic instability, significant dysrhythmias, seizures, or complications of prolonged unconsciousness.
Intensive care
ICU treatment may be required for respiratory failure, coma requiring airway protection, shock, or life-threatening cardiac toxicity.
Discharge
Discharge requires return to baseline mental status, adequate spontaneous ventilation, stable vital signs, safe mobility, and assessment of relevant coingestants.
A fixed six-hour observation period is not appropriate for all agents and formulations.
An intentional ingestion also requires appropriate mental health assessment.
17. Expected course and prognosis
Isolated Z-drug overdoses usually resolve with supportive care, often within several hours.
Recovery may be prolonged with modified-release preparations, large doses, impaired metabolism, or coingested CNS depressants.
Older sedatives may produce coma lasting more than a day, especially after large ingestions.
Severe chloral hydrate poisoning can be fatal because of ventricular dysrhythmias.
Severe meprobamate poisoning can produce prolonged coma and circulatory collapse.
Long-term complications are more likely to result from hypoxia, aspiration, cardiovascular collapse, or prolonged immobility than from uncomplicated transient sedation.
18. Clinical pitfalls
Treating buspirone as a conventional sedative-hypnotic. It is a primarily serotonergic anxiolytic and has a different toxicity profile.
Classifying tramadol as a hypnotic. It is an opioid with additional serotonergic effects and important seizure risk.
Assuming every Z-drug overdose is harmless. Coingestants and serious respiratory depression can produce fatal outcomes.
Ignoring complex sleep behaviors. Serious injury can occur even during prescribed Z-drug use.
Assuming pulse oximetry excludes hypoventilation. Capnography or blood gas assessment may be necessary.
Administering flumazenil routinely. It can precipitate seizures in susceptible or mixed-overdose patients.
Assuming flumazenil reverses chloral hydrate poisoning. Its effectiveness has not been established.
Overlooking chloral hydrate cardiotoxicity. ECG monitoring is essential after significant exposure.
Using beta blockers without considering circulatory status. Chloral hydrate-associated dysrhythmia treatment requires specialist judgment.
Performing routine gastric lavage or whole-bowel irrigation. Neither is established as standard treatment.
Giving charcoal to an unprotected sedated patient. Aspiration can cause serious complications.
Assuming dialysis is useful for every sedative. Evidence supports consideration only in selected severe poisonings, particularly involving meprobamate.
Using a universal six-hour discharge rule. Recovery times vary substantially.
Stopping long-term sedative treatment abruptly without assessing dependence. Withdrawal can occasionally be severe.
Key clinical conclusions
Sedative-hypnotic poisoning is not a single clinical syndrome because the medications grouped under this heading differ markedly in pharmacology and toxicity.
Zolpidem, zaleplon, and eszopiclone generally produce sedation, with severe respiratory toxicity more likely when other CNS depressants are involved.
Chloral hydrate can cause life-threatening ventricular dysrhythmias, while meprobamate and glutethimide may produce prolonged coma and cardiovascular instability.
Buspirone and tramadol require separate toxicologic consideration.
The mainstay of treatment is airway and ventilatory support, careful monitoring, management of coingestants, and agent-specific treatment of complications.
Flumazenil should be reserved for carefully selected circumstances. Routine lavage, charcoal administration, and extracorporeal elimination are not appropriate for most cases.